ATRA Projected Dividend Yield
Atara Biotherapeutics Inc ( NASDAQ : ATRA )Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. Co. is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. Co.'s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. 21 YEAR PERFORMANCE RESULTS |
ATRA Dividend History Detail ATRA Dividend News ATRA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |